Raymond James Initiates Coverage On Jazz Pharmaceuticals with Market Perform Rating
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman has initiated coverage on Jazz Pharmaceuticals with a Market Perform rating.
September 29, 2023 | 9:26 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jazz Pharmaceuticals has been initiated with a Market Perform rating by Raymond James.
Analyst ratings often influence the short-term performance of a stock. A Market Perform rating suggests that the analyst expects the stock to perform similarly to the overall market, neither outperforming nor underperforming significantly. This could lead to neutral short-term impact on Jazz Pharmaceuticals' stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100